2. Amyotrophic lateral sclerosis Clinical trials / Disease details

Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2014-002228-28-IT (EUCTR)	01/09/2014	12/06/2014	STEMALS-II	A double blind, placebo controlled, parallel groups, multicenter study on filgrastim in amyotrophic lateral sclerosis - STEMALS-II	Amyotrophic lateral sclerosis (ALS) is a severe progressive neurological disorder characterized by a selective degeneration of spinal, bulbar, and cortical motor neurons.;Therapeutic area: Not possible to specify	Trade Name: TEVAGRASTIM Product Name: filgrastim Trade Name: MANNITOLO 18% LDB Product Name: MANNITOLO 18% Trade Name: PERFALGAN Product Name: PARACETAMOLO	Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino	NULL	Not Recruiting			Female: yes Male: yes	90	Phase 2	Italy
2	NCT02236065 (ClinicalTrials.gov)	August 2014	8/9/2014	Combination Therapy of Cord Blood and G-CSF for Patients With Brain Injury or Neurodegenerative Disorders	A Pilot Study of Combination Therapy of Allogeneic Umbilical Cord Blood and Granulocyte-colony Stimulating Factor for Patients With Brain Injury or Neurodegenerative Disorders	Brain Injury;Cerebral Palsy;Amyotrophic Lateral Sclerosis;Parkinson's Disease	Procedure: Umbilical cord blood therapy;Biological: Filgrastim	MinYoung Kim, M.D.	NULL	Completed	19 Years	75 Years	All	10	N/A	Korea, Republic of
3	NCT01825551 (ClinicalTrials.gov)	November 2012	13/3/2013	The Effect of GCSF in the Treatment of ALS Patients	The Effect of Granulocyte Colony Stimulating Factor (GCSF) in the Treatment of Amyotrophic Lateral Sclerosis (ALS) Patients Referred to Tehran Imam Khomeini and Shariati Hospital Centers in 2013	Amyotrophic Lateral Sclerosis	Drug: Granulocyte Colony Stimulating Factor;Drug: Placebo	Tehran University of Medical Sciences	NULL	Completed	18 Years	85 Years	Both	40	Phase 2/Phase 3	Iran, Islamic Republic of
4	NCT00397423 (ClinicalTrials.gov)	December 2006	8/11/2006	G-CSF Treatment for Amyotrophic Lateral Sclerosis: A RCT Study Assessing Clinical Response	Granulocyte-Colony Stimulating Factor Treatment for Amyotrophic Lateral Sclerosis: A Randomized Control Trial Study Assessing Clinical Response	Amyotrophic Lateral Sclerosis	Drug: Granulocyte Colony Stimulating Factor;Drug: NS	Peking University	NULL	Completed	18 Years	65 Years	Both	40	Phase 2	China
5	NCT00298597 (ClinicalTrials.gov)	March 2006	1/3/2006	Influence of G-CSF and EPO on Associative Learning and Motor Skills	Influence of G-CSF and EPO on Associative Learning and Motor Skills	Chronic Stroke;Amyotrophic Lateral Sclerosis	Drug: granulocyte - colony stimulating factor (G-CSF);Drug: erythropoetin (EPO)	University Hospital Muenster	NULL	Completed	18 Years	N/A	Both	180	Phase 2	Germany